Short-Term Risk of Serious Fall Injuries in Older Adults Initiating and Intensifying Treatment With Antihypertensive Medication

Daichi Shimbo, MD; C. Barrett Bowling, MD, MSPH; Emily B. Levitan, ScD; Luqin Deng, PhD; John J. Sim, MD; Lei Huang, MSPH; Kristi Reynolds, PhD, MPH; Paul Muntner, PhD

Background—Antihypertensive medication use has been associated with an increased risk of falls in some but not all studies. Few data are available on the short-term risk of falls after antihypertensive medication initiation and intensification.

Methods and Results—We examined the association between initiating and intensifying antihypertensive medication and serious fall injuries in a case-crossover study of 90,127 Medicare beneficiaries who were ≥65 years old and had a serious fall injury between July 1, 2007, and December 31, 2012, based on emergency department and inpatient claims. Antihypertensive medication initiation was defined by a prescription fill with no fills in the previous year. Intensification was defined by the addition of a new antihypertensive class, and separately, titration by the addition of a new class or increase in dosage of a current class. Exposures were ascertained for the 15 days before the fall (case period) and six 15-day earlier periods (control periods). Overall, 272, 1508, and 3113 Medicare beneficiaries initiated, added a new class of antihypertensive medication or titrated therapy within 15 days of their serious fall injury. The odds for a serious fall injury was increased during the 15 days after antihypertensive medication initiation (odds ratio, 1.36 [95% confidence interval, 1.19–1.55]), adding a new class (odds ratio, 1.16 [95% confidence interval, 1.10–1.23]), and titration (odds ratio, 1.13 [95% confidence interval, 1.08–1.18]). These associations were attenuated beyond 15 days.

Conclusions—Antihypertensive medication initiation and intensification was associated with a short-term, but not long-term, increased risk of serious fall injuries among older adults. (Circ Cardiovasc Qual Outcomes. 2016;9:222-229. DOI: 10.1161/CIRCOUTCOMES.115.002524.)

Key Words: accidental falls ■ aged ■ antihypertensive agents ■ geriatrics

The benefit of antihypertensive medication on cardiovascular disease risk reduction has been demonstrated among older adults in randomized controlled trials. However, there may be unintended harm associated with antihypertensive medication use in older adults. Older adults are susceptible to adverse side effects associated with antihypertensive medication use, including postural hypotension, balance and gait impairment, dizziness, and electrolyte disturbances, which may increase the risk of serious falls injuries. Clinicians often weigh the cardiovascular disease risk-reduction benefits of antihypertensive medications against their potential for inducing fall injuries among older adults. Some, but not all, studies suggest that antihypertensive medication use in older adults is associated with an increased risk for falls or injuries related to falls including fractures. Because most studies have examined prevalent users of antihypertensive medication, the relevance of these findings to clinical decision making on antihypertensive medication initiation or intensification is limited. Also, few data are available on the short-term versus long-term risk for falls after initiation or intensification of antihypertensive medication. Determining whether antihypertensive medication initiation or intensification is associated with an increased risk for serious fall injuries and identifying a hazard period associated with increased risk have important implications, given the large number of older adults initiating and titrating antihypertensive medication and the availability of preventive strategies to reduce falls risk. We determined whether antihypertensive medication initiation is associated with a short-term increased risk for a serious fall injury among older US adults and whether the risk for a serious fall injury is similarly increased after antihypertensive medication intensification. We also examined the long-term fall injury risk after antihypertensive medication initiation and intensification.

Methods

We conducted 2 types of analyses using a national 5% random sample of Medicare beneficiaries from 2006 through 2012. The first analysis...
WHAT IS KNOWN

• In older adults, antihypertensive medication use has been associated with an increased risk of falls in some but not all studies.
• Few data are available on the short-term versus long-term risk for falls after initiation or intensification of antihypertensive medication in older adults.

WHAT THE STUDY ADDS

• Using Medicare claims from 2007 through 2012, we found that although the risk of a serious fall injury was low, there was a short-term increased risk of a serious fall injury within a 15-day period after initiation or intensification of antihypertensive medication.
• In contrast, the association between antihypertensive medication initiation or intensification and a serious fall injury was attenuated beyond 15 days.
• The results of this study suggest that antihypertensive medication initiation and intensification was associated with a short-term, but not long-term, increased risk of serious fall injuries among older adults.

was a retrospective cohort study, which was used to estimate the absolute risk for serious fall injuries among beneficiaries initiating and adding a new antihypertensive medication class or titrating antihypertensive medication. The second analysis was a case-crossover study of Medicare beneficiaries who experienced a serious fall injury. The case-crossover study was used to determine whether initiating and adding a new class or titrating antihypertensive medication were associated with an increased risk for serious fall injuries. Data used for the current analyses include claims from Medicare fee-for-service parts A (inpatient), B (outpatient), and D (prescription drug). Institutional review boards at the University of Alabama at Birmingham and the Center for Medicare and Medicaid Services approved this analysis.

Retrospective Cohort Study

Medicare beneficiaries who initiated antihypertensive medication between January 1, 2007, and December 31, 2011, were included in the retrospective cohort used to estimate the absolute risk for serious fall injuries in the 15 days after initiating and adding a new class and titration of treatment (Figure I in the Data Supplement). Initiation was defined by a Medicare Part D claim for antihypertensive medication with 365 continuous days of Medicare fee-for-service coverage (parts A, B, and D but not C) before the fill with no claims for antihypertensive medication. Medicare beneficiaries enrolled in a managed care program (part C) during this time period were not included because this is a capitated program and claims for these individuals are not complete. The date of the antihypertensive medication fill is provided with the claim. All medication classes filled within the 7 days after the date of initiation were included as part of the initiation regimen.14 We restricted the sample to beneficiaries with hypertension, defined by 1 or more outpatient physician evaluation and management claims with International Classification of Diseases, Ninth Revision diagnoses of 401.x (malignant, benign, or unspecified essential hypertension) during the 365 days before each beneficiary’s first fill. We included Medicare beneficiaries with age ≥265 years old and <110 years old at the start of the look-back period (365 days before the first antihypertensive medication fill) and having continuous residence in the United States during the look-back period to provide information for the general population of older US adults. Adding a new class of antihypertensive medication was defined by a Medicare part D claim for a class of antihypertensive medication other than those filled on initiation. Titration was defined by adding a new class of antihypertensive medication or an increase in the dosage of the medication class filled on initiation. Adding a new antihypertensive medication class and titration were studied in the 365 days after initiation. Therefore, for these analyses, follow-up occurred through December 31, 2012.

Case-Crossover Study

The case-crossover study design is useful for investigating the transient effect of an exposure.16–18 Using this study design, only individuals who experience an outcome are analyzed, and each case serves as their own control. Medicare beneficiaries who experienced a serious fall injury event between July 1, 2007, and December 31, 2012, formed the base population for these analyses (Figure II in the Data Supplement). We used International Classification of Diseases, Ninth Edition, Clinical Modification and current procedure terminology codes to identify these events. Serious fall injuries were defined as emergency department and inpatient claims with a fall-related E code (8800–8889) and an injury code for nonpathological skull, facial, cervical, clavicle, humeral, forearm, pelvic, hip, fibula, tibia, or ankle fractures (80000–80619, 8070–8072, 8080–8089, 81000–81419, 8180–8251, or 8270–8291), brain injury (85200–85239), or dislocation of the hip, knee, shoulder, or jaw (8300–8321, 83500–83513, or 83630–83660).9 In the absence of a fall-related E code, an emergency department or inpatient claim with any of these codes was considered a serious fall injury as long as there was no motor vehicle accident E code (8100–8199).9 We required all beneficiaries to have at least 560 days of continuous Medicare fee-for-service coverage preceding the date of their serious fall injury. As described below, the 560-day interval includes the 195-day period (days 0–194) between the index date and the start of the earliest control period, and a 365-day period (days 195–559) before the earliest control period, which was used for assessing antihypertensive medication use and clinical characteristics. We restricted the population to Medicare beneficiaries with age ≥265 years old and <110 years old 560 days before their fall injury and having continuous residence in the United States during the 560 days before their fall injury. For each beneficiary, we included the first occurrence of a serious fall injury meeting the above criteria. The date of the serious fall injury diagnosis was assigned as the index date.

The primary exposure was the initiation of antihypertensive medication. The case period was defined as the 15 days before and including the index date (days 0–14) and we selected six 15-day control periods (30–44, 60–74, 90–104, 120–134, 150–164, and 180–194 days before the index date). A schematic representation of this study design is presented in the Figure. For the case period and each control period, initiation of antihypertensive medication was defined by a claim in Medicare Part D for an angiotensin-converting enzyme inhibitor, aldosterone antagonist, angiotensin receptor blocker, ß-blocker, ß-blocker, calcium channel blocker, central acting agent, diuretic (thiazide-type, loop, or potassium sparing), renin inhibitor, or vasodilator with no claims for any of the antihypertensive classes during the 365 days before the first antihypertensive medication fill. These drugs were identified using National Drug Codes.

The risk for serious fall injuries associated with 2 secondary exposures representing antihypertensive medication intensification was examined: (1) addition of a new class of antihypertensive medication, and alternatively (2) antihypertensive medication titration. Addition of a new class of antihypertensive medication was defined as a fill for a class of antihypertensive medication within the case period or, separately, the control periods with no fills for that drug class during the preceding 365 days. Medication titration was defined as the addition of a new class of antihypertensive medication or an increase in the dosage of a medication class during the case or control periods.

Characteristics of Medicare Beneficiaries

Age, race/ethnicity, sex, region of residence, and calendar month of the fall were obtained from the Medicare beneficiary summary file. Using previously published algorithms,19–25 we identified a history of diabetes mellitus, coronary heart disease, heart failure, stroke,
chronic kidney disease, syncope, osteoporosis, depression, or dementia. In addition, based on part D claims and National Drug Codes, the number of different generic medications, besides antihypertensive medications, that each beneficiary filled was determined. The Charlson score, a measure of overall comorbidity, was calculated. In addition, a skilled nursing facility stay and any hospitalizations were identified in Medicare claims. These characteristics were identified at the time of initiation of antihypertensive medication for the retrospective cohort study and on the 365 days before the index date for the case-crossover study.

**Statistical Analysis**

For the retrospective cohort study, we calculated the percentage of Medicare beneficiaries experiencing a serious fall injury within 15 days after antihypertensive medication initiation. Among Medicare beneficiaries who initiated antihypertensive medication, characteristics at the time of initiation were calculated for those who experienced and did not experience a serious fall injury within 15 days. We then calculated the percentage of Medicare beneficiaries experiencing a serious fall injury within 15 days after adding a new antihypertensive medication class and medication titration.

For the case-crossover study, the characteristics of all Medicare beneficiaries who experienced a serious fall injury and those who experienced a serious fall injury within 15 days after initiation of antihypertensive medication were calculated. The distribution of classes of antihypertensive medication that were initiated in the 15-day case period and the 6 control periods were calculated for the overall sample and among Medicare beneficiaries with 1 or more diagnoses of hypertension. Because some drugs, classified as antihypertensive medication, may be prescribed for indications other than hypertension, sensitivity analyses were conducted in which the definitions of initiation, addition of a new antihypertensive medication class, and antihypertensive medication titration also required having 1 or more diagnoses of hypertension (International Classification of Diseases, Ninth Revision diagnoses of 401.xx) in the 365 days before the case or control period. Furthermore, because being hospitalized could result in an increased risk for falls and may be associated with initiation of antihypertensive medication, sensitivity analyses were conducted after excluding beneficiaries who were hospitalized in the 365 days before their serious fall injury. The odds ratio and 95% confidence interval (95% CI) for a serious fall injury associated with initiation of antihypertensive medication in the case period (0–14 days before the fall) were calculated using conditional logistic regression accounting for each beneficiary having 6 control periods (Table 1). Analyses were repeated using 1 (60–74 days before the fall) instead of 6 control periods. Cumulative mortality through 90 days after having a serious fall injury was calculated using conditional logistic regression accounting for each beneficiary having 6 control periods for each case period before the index date (ie, date of the serious fall injury; Table 1). Analyses were also repeated using 1 control period for each of the 3 case periods.

In exploratory analyses, odds ratios (95% CI) for a serious fall injury were also calculated within prespecified subgroups defined by demographics and the presence of medical comorbidities, which are associated with an increased risk of falls. Some studies have suggested that specific classes of antihypertensive medication are associated with a higher risk of falls or fractures. Furthermore, the majority of older US adults on antihypertensive medication are taking 2 or more classes. Therefore, prespecified analyses were also conducted for subgroups defined by antihypertensive medication class and also the number of antihypertensive medication classes. Differences across subgroups were calculated using multiplicative interaction terms.

The case-crossover analyses were repeated to assess the association between adding a new class of antihypertensive medication and antihypertensive medication titration and the odds ratios for serious fall injuries. Analyses were conducted using SAS version 9.3 (SAS Institute, Cary, NC).

**Results**

### Risk for Serious Fall Injuries in the Retrospective Cohort Study

Between January 1, 2007, and December 31, 2011, 65,210 Medicare beneficiaries who met the inclusion criteria initiated antihypertensive medication. Of this population, 186 (0.29%) Medicare beneficiaries had a serious fall injury within 15 days after treatment initiation. Beneficiaries who

<table>
<thead>
<tr>
<th>Case Period</th>
<th>Control Period (Primary Analyses)</th>
<th>Control Period (Secondary Analyses)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0–14 d</td>
<td>Six control periods, d 30–44 60–74 90–104 120–134 150–164 180–194</td>
<td>One control period, d 60–74</td>
</tr>
<tr>
<td>30–44 d</td>
<td>Four control periods 90–104 days 120–134 days 150–164 days 180–194 days</td>
<td>One control period, d 120–134</td>
</tr>
<tr>
<td>90–104 d</td>
<td>Three control periods, d 120–134 150–164 180–194</td>
<td>One control period, d 150–164 days</td>
</tr>
</tbody>
</table>
initiated antihypertensive medication and had a serious fall injury within 15 days were older; less likely to be male; more likely to have a history of coronary heart disease, heart failure, stroke, syncope, osteoporosis, depression, and dementia; and were taking more medication classes, have a higher Charlson comorbidity index, and be hospitalized or in a skilled nursing facility in the prior year (Table I in the Data Supplement). Within 365 days after antihypertensive medication initiation, 23315 and 30143 beneficiaries added a class of antihypertensive medication and titrated their antihypertensive medication, respectively. A serious fall injury occurred within 15 days after adding a new class of antihypertensive medication for 0.27% (n=64) of beneficiaries and within 15 days after titration for 0.29% (n=88) of beneficiaries.

### Short-Term Risk of Serious Fall Injuries Associated With Antihypertensive Medication in the Case-Crossover Study

Table 2 shows the characteristics of the 90127 Medicare beneficiaries who had a serious fall injury between January 1, 2007, and December 31, 2012, and of the subset of 272 individuals who initiated antihypertensive medication in the 15 days before their fall. Of those initiating antihypertensive medication, 30.9%, 34.6%, and 34.6% were aged 65 to 74 years, 75 to 84 years, and ≥85 years, respectively; 28.3% were male; and 89.7% were white.

Overall, 272, 1508, and 3113 Medicare beneficiaries initiated, added a new class of antihypertensive medication, and titrated therapy, respectively, within 15 days before their serious fall injury. The short-term odds ratios (95% CI) for a serious fall injury were 1.36 (95% CI, 1.19–1.55) for initiation of antihypertensive medication, 1.16 (95% CI, 1.10–1.23) for adding a new antihypertensive medication class, and 1.13 (95% CI, 1.08–1.18) for antihypertensive medication titration (Table 3). The associations were similar when the definition of
The association between antihypertensive mediation initiation, addition, and titration required 1 or more diagnoses of hypertension and when the population was restricted to Medicare beneficiaries without a recent hospitalization. The associations were similar using 1 control period (Table II in the Data Supplement). Among Medicare beneficiaries with a serious fall injury within 15 days after antihypertensive medication initiation, addition of new class, and titration, 14.0%, 15.6%, and 14.6%, respectively, died within 90 days after the fall.

**Antihypertensive Medication Class Initiated in Case Versus Control Periods**

Initiation of diuretics, particularly loop diuretics, was more common in the 15-day case period compared with the control periods (Table III in the Data Supplement). Initiation with other classes of antihypertensive medication was similar in the case and control periods. The percentage of beneficiaries who simultaneously initiated >1 antihypertensive class was higher in the case period (20.2%) compared with the control periods (17.4%). These results were similar when the definition of antihypertensive medication initiation required 1 or more diagnoses of hypertension and when the population was restricted to Medicare beneficiaries without a recent hospitalization.

**Subgroup Analyses**

The association between antihypertensive medication initiation and serious fall injuries did not vary by subgroup (Table IV in the Data Supplement). The short-term odds ratio for a serious fall injury associated with the addition of a new class of antihypertensive medication was stronger for Medicare beneficiaries without a history of diabetes mellitus, without heart failure, and who were taking fewer nonantihypertensive medications (Table V in the Data Supplement). The short-term odds ratio for a serious fall injury associated with the titration of antihypertensive medication was stronger for older Medicare beneficiaries, those without a history of heart failure, and those without chronic kidney disease (Table VI in the Data Supplement). The associations of initiation and addition of antihypertensive medication with serious fall injuries did not vary by medication class or the number of classes initiated (Table VII in the Data Supplement) or added (Table VIII in the Data Supplement).

**Long-Term Risk of Serious Fall Injuries**

No association was present between initiating antihypertensive medications, and, separately, adding a new class of antihypertensive medication in the 30 to 44 days, 60 to 74 days, or 90 to 104 days before a fall, and the risk for a subsequent fall injury (Table 4). The odds ratio for a serious fall injury associated with the titration of antihypertensive medication within 30 to 44 days, 60 to 74 days, and 90 to 104 days before the fall was 1.04 (95% CI, 1.00–1.09), 1.05 (95% CI, 1.00–1.09), and 1.04 (95% CI, 1.00–1.09), respectively. The associations were similar in analyses using 1 instead of 6 control periods (Table IX in the Data Supplement).

**Discussion**

Falls risk among elderly individuals is a major public health concern. Falls are often attributed to the interaction of long-term predisposing conditions and short-term precipitating factors. The high rate of falls and risk for adverse outcomes after a fall has generated an increasing recognition of the need to identify precipitating factors for falls in older adults. In the current study, the odds for a serious fall injury were increased in the 15 days after antihypertensive medication initiation and intensification. An increased risk for a serious fall injury was no longer present >15 days after either initiation or adding a new class and was attenuated >15 days after titration of antihypertensive medication.

Previous studies of the short-term risks after antihypertensive medication initiation have focused on fractures as an outcome rather than the risk of falls or injuries related to falls. For example, Butt et al. showed that hip fracture risk was...
Margolis et al did not find an increased risk for self-reported participants with diabetes mellitus enrolled in the Action to Prevent ous fall injury. In a substudy of 3099 middle age and older hypertensive medication intensification and the risk of a seri- vity by the class of antihypertensive medication initiated. Before the fall but not beyond 15 days. This association did not increased odds ratio for a serious fall injury was present when and calcium channel blockers were not. In the current study, an each significantly associated with an increased risk of hip frac- cation among Ontario residents who were ≥66 years. Initiation of angiotensin-converting enzyme inhibitors and β-blockers was each significantly associated with an increased risk of hip frac- tures, whereas thiazide diuretics, angiotensin receptor blockers, and calcium channel blockers were not. In the current study, an increased odds ratio for a serious fall injury was present when antihypertensive medication was initiated in a 15-day period before the fall but not beyond 15 days. This association did not vary by the class of antihypertensive medication initiated.

Scarcce data are available on the association between anti- hypertensive medication intensification and the risk of a seri- ous fall injury. In a study of 3099 middle age and older participants with diabetes mellitus enrolled in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, Margolis et al did not find an increased risk for self-reported falls or nonspine fractures between participants randomized to a systolic pressure of <120 mmHg versus systolic pressure of <140 mmHg. It is unclear whether these results are applicable for older adults who undergo antihypertensive medication intensification because the ACCORD substudy participants were relatively young (mean age 62 years old) and the outcomes were ascertained years after reductions in blood pressure had occurred in the intensive treatment arm. In the current study, there was no long-term increased risk for serious falls injuries associated with antihypertensive medication use, a finding that is consistent with the findings from ACCORD.[11]

The Systolic Blood Pressure Intervention Trial (SPRINT) recently demonstrated that a systolic blood pressure target goal of 120 mmHg (intensive treatment) versus 140 mmHg (conventional treatment) was associated with a lower risk of cardio- vascular disease events and mortality in adults at least 50 years of age with a systolic blood pressure of 130 to 180 mmHg and high cardiovascular risk but without diabetes mellitus or a previous stroke.[3] The intensive versus conventional treatment goal was associated with a higher risk of hypotension, syncope, electrolyte abnormalities, but not injurious falls, defined as falls that resulted in evaluation in an emergency department or hospitalization. However, when adverse events were classified as possibly or definitely related to intensive treatment, the risk of injurious falls was higher in the intensive versus conventional treatment arm (0.8% versus 0.5%; P=0.05). The results from the current study indicating a short-term increased risk of serious fall injuries after antihypertensive medication.

Table 4. Short-Term and Long-Term Odds Ratios for a Serious Fall Injury Associated With Initiation, Addition of New Class, and Titration of Antihypertensive Medication

<table>
<thead>
<tr>
<th>Case Period (d)</th>
<th>Case Period n (%)‡</th>
<th>Control Periods n (%)§</th>
<th>OR (95% CI)</th>
<th>Case Period (d)</th>
<th>Case Period n (%)‡</th>
<th>Control Periods n (%)§</th>
<th>OR (95% CI)</th>
<th>Case Period (d)</th>
<th>Case Period n (%)‡</th>
<th>Control Periods n (%)§</th>
<th>OR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Initiation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0–14†</td>
<td>272 (0.30)</td>
<td>1201 (0.22)</td>
<td>1.36 (1.19, 1.55)</td>
<td>159 (0.18)</td>
<td>701 (0.13)</td>
<td>1.36 (1.15, 1.62)</td>
<td>146 (0.24)</td>
<td>635 (0.18)</td>
<td>1.38 (1.15, 1.65)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>30–44¶</td>
<td>201 (0.22)</td>
<td>1000 (0.22)</td>
<td>1.01 (0.86, 1.17)</td>
<td>133 (0.15)</td>
<td>568 (0.13)</td>
<td>1.17 (0.97, 1.41)</td>
<td>100 (0.17)</td>
<td>535 (0.18)</td>
<td>0.93 (0.75, 1.16)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>60–74#</td>
<td>195 (0.22)</td>
<td>805 (0.22)</td>
<td>0.97 (0.83, 1.13)</td>
<td>116 (0.13)</td>
<td>452 (0.13)</td>
<td>1.03 (0.84, 1.26)</td>
<td>111 (0.18)</td>
<td>424 (0.18)</td>
<td>1.05 (0.85, 1.29)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>90–104**</td>
<td>201 (0.22)</td>
<td>604 (0.22)</td>
<td>1.00 (0.85, 1.17)</td>
<td>116 (0.13)</td>
<td>338 (0.12)</td>
<td>1.04 (0.84, 1.28)</td>
<td>102 (0.17)</td>
<td>322 (0.18)</td>
<td>0.95 (0.76, 1.19)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Addition of new class</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0–14†</td>
<td>1508 (1.67)</td>
<td>7820 (1.45)</td>
<td>1.16 (1.10–1.23)</td>
<td>1276 (1.42)</td>
<td>6664 (1.23)</td>
<td>1.15 (1.09–1.23)</td>
<td>687 (1.14)</td>
<td>3450 (0.95)</td>
<td>1.20 (1.10–1.30)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>30–44¶</td>
<td>1361 (1.51)</td>
<td>6459 (1.43)</td>
<td>1.05 (0.99–1.12)</td>
<td>1160 (1.29)</td>
<td>5504 (1.22)</td>
<td>1.06 (0.99–1.13)</td>
<td>577 (0.96)</td>
<td>2873 (0.95)</td>
<td>1.00 (0.92–1.1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>60–74#</td>
<td>1346 (1.49)</td>
<td>5113 (1.42)</td>
<td>1.05 (0.99–1.12)</td>
<td>1146 (1.27)</td>
<td>4355 (1.21)</td>
<td>1.05 (0.99–1.12)</td>
<td>595 (0.99)</td>
<td>2278 (0.95)</td>
<td>1.05 (0.95–1.15)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>90–104**</td>
<td>1290 (1.43)</td>
<td>3823 (1.41)</td>
<td>1.01 (0.95–1.08)</td>
<td>1105 (1.23)</td>
<td>3253 (1.20)</td>
<td>1.02 (0.95–1.09)</td>
<td>567 (0.94)</td>
<td>1711 (0.95)</td>
<td>0.99 (0.90–1.00)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Titration</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0–14†</td>
<td>3113 (3.45)</td>
<td>16714 (3.09)</td>
<td>1.13 (1.08–1.18)</td>
<td>2968 (2.99)</td>
<td>14542 (2.69)</td>
<td>1.12 (1.08–1.17)</td>
<td>1432 (2.38)</td>
<td>7662 (2.12)</td>
<td>1.13 (1.07–1.20)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>30–44¶</td>
<td>2874 (3.19)</td>
<td>13840 (3.07)</td>
<td>1.04 (1.00–1.09)</td>
<td>2510 (2.78)</td>
<td>12032 (2.67)</td>
<td>1.05 (1.00–1.10)</td>
<td>1275 (2.12)</td>
<td>6367 (2.12)</td>
<td>1.00 (0.94–1.06)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>60–74#</td>
<td>2685 (3.18)</td>
<td>10975 (3.04)</td>
<td>1.05 (1.00–1.09)</td>
<td>2511 (2.79)</td>
<td>9521 (2.64)</td>
<td>1.06 (1.01–1.11)</td>
<td>1302 (2.16)</td>
<td>5065 (2.11)</td>
<td>1.03 (0.96–1.09)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>90–104**</td>
<td>2820 (3.13)</td>
<td>8155 (3.02)</td>
<td>1.04 (1.00–1.09)</td>
<td>2434 (2.70)</td>
<td>7067 (2.62)</td>
<td>1.03 (0.98–1.08)</td>
<td>1280 (2.13)</td>
<td>3805 (2.11)</td>
<td>1.01 (0.95–1.08)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*For the previous hypertension diagnosis, definitions of initiation, addition of a new antihypertensive medication class, and antihypertensive medication titration additionally required having 1 or more diagnoses of hypertension (International Classification of Diseases, Ninth Revision diagnoses of 401.xx) in the 365 days before the case or control period.
†Beneficiaries who were hospitalized within 365 days before their serious fall injury were excluded.
‡Calculated as 100 times (number of serious fall injuries in case period divided by total number of serious fall injuries).
§Calculated as 100 times (total number of serious fall injuries across the control periods divided by the product of number of control periods times total number of serious fall injuries).
**Three control periods: 120–134, 150–164, and 180–194 d before the fall.
intensification but no increased risk with long-term antihypertensive medication use are consistent with the findings in SPRINT. It was reported that 7.6% or 16.8 million of US adults meet the SPRINT eligibility criteria. Therefore, many older US adults may have their antihypertensive medication intensified to reach a lower systolic blood pressure target and be susceptible to a short-term increased risk of serious fall injuries.

Some, but not all, studies have reported that antihypertensive medication use in older adults is associated with an increased risk for falls or fall injuries. Tinetti et al conducted a retrospective cohort study and found that in clinical practice, Medicare beneficiaries >70 years of age who were taking antihypertensive medication had a higher risk of a serious fall injury than their counterparts not taking antihypertensive medication. Using a case-crossover study design, which minimizes confounding by having each individual serve as his/her own control, we have extended the results of Tinetti et al to demonstrate that antihypertensive medication initiation and intensification may be associated with a short-term increased risk of serious fall injuries in older adults.

Using a retrospective cohort study design, we also showed that the risk of a serious fall injury was low within 15 days after initiating antihypertensive medication, adding a new class, and titrating antihypertensive medication. However, the risk for a fall after antihypertensive initiation and intensification is likely to be substantially higher, as serious fall injuries represent only 10% of all falls experienced by older adults. Serious fall injuries, including fractures, brain injuries, and dislocations, are the most adverse consequences of falls in older adults. Nonetheless, falls that do not result in a serious injury are also clinically important as they are associated with functional decline and nursing home placement in older adults.

There are several potential mechanisms for the short-term increased risk of serious falls associated with antihypertensive medication initiation and intensification. Older adults are at increased risk for postural hypotension, which may result in neurological effects and consequently balance and gait impairment. In addition, antihypertensive medication-induced electrolyte disturbances may cause neurological and physical side effects, which may make older adults more susceptible to falls. Multicomponent interventions that include multiple risk factor assessment, physical therapy, and exercise are effective in falls prevention. These strategies could be adopted by clinicians in the short-term to prevent falls and fall-related injuries when antihypertensive medication is initiated or intensified in their older patients.

There are several strengths of the current study. Given the longitudinal nature of Medicare claims, we were able to study serious injuries after antihypertensive medication initiation and intensification. Another strength of the study is that Medicare provides data that are highly generalizable to older adults in the United States. Some limitations must be noted. The generalizability to younger adults may be limited. Also, as with all claims-based analyses, the results depend on the accuracy of coding of disease states and pharmacy fills. Because blood pressure data are not available in Medicare claims, we could not determine whether the associations we report can be explained by changes in blood pressure levels. Because there was a lack of information on falls that did not result in a serious injury, we could not determine whether antihypertensive medication initiation or intensification was associated with less serious falls. Another potential limitation is the assumption that clinical characteristics were stable over time in the case-crossover study. Given that the duration between the control periods and the case period was relatively short (195 days or less), it is likely that substantial changes in clinical characteristics did not occur. It was not possible to determine the exact timing between antihypertensive medication initiation and intensification and the occurrence of the serious fall injury using Medicare claims. However, the inability to pinpoint the timing of the outcome and the appropriate time window for the exposure will likely bias results toward the null. Therefore, if the exact time course were known, the associations of antihypertensive medication initiation and intensification with the risk of serious fall injuries would be even stronger. Finally, although the case-crossover study demonstrated that antihypertensive medication initiation and intensification are associated with an increased risk of serious fall injuries, caution is warranted when concluding the results indicate causality.

In conclusion, the results of the current study indicate that the initiation and intensification of antihypertensive medication are associated with a short-term increased risk of a serious fall injury in older adults. However, the short-term risk of a serious fall injury is low, and there does not seem to be a long-term increased risk for serious fall injuries associated with antihypertensive medication. The short-term risk of serious fall injuries, as well as approaches, for reducing this risk should be discussed with older patients when initiating or intensifying antihypertensive medication.

Sources of Funding
This work was supported by the National Institutes of Health (K24-HL125704) from the National Heart, Lung, and Blood Institute, Bethesda, MD.

Disclosures
Drs Muntner and Levitan have received institutional grants from Amgen Inc. unrelated to the topic of the current article. The other authors report no conflicts.

References

Chronic condition data w

Epidemiology Circulation Infarction Onset Study. 2012;125:491–496. doi: 10.1161/


Short-Term Risk of Serious Fall Injuries in Older Adults Initiating and Intensifying Treatment With Antihypertensive Medication
Daichi Shimbo, C. Barrett Bowling, Emily B. Levitan, Luqin Deng, John J. Sim, Lei Huang, Kristi Reynolds and Paul Muntner

_Circ Cardiovasc Qual Outcomes_. 2016;9:222-229; originally published online May 10, 2016; doi: 10.1161/CIRCOUTCOMES.115.002524
_Circulation: Cardiovascular Quality and Outcomes_ is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2016 American Heart Association, Inc. All rights reserved.
Print ISSN: 1941-7705. Online ISSN: 1941-7713

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circoutcomes.ahajournals.org/content/9/3/222

Data Supplement (unedited) at:
http://circoutcomes.ahajournals.org/content/suppl/2016/05/10/CIRCOUTCOMES.115.002524.DC1

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in _Circulation: Cardiovascular Quality and Outcomes_ can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to _Circulation: Cardiovascular Quality and Outcomes_ is online at:
http://circoutcomes.ahajournals.org//subscriptions/
SUPPLEMENTAL MATERIAL
Supplemental Table 1. Characteristics of Medicare beneficiaries in the retrospective cohort study who had and did not have a serious fall injury within 15 days following initiation of antihypertensive medication

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>With serious fall injury (N=186)</th>
<th>Without serious fall injury (N=65,024)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at initiation of antihypertensive medication</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;75 years</td>
<td>56 (30.1%)</td>
<td>31,057 (47.8%)</td>
</tr>
<tr>
<td>75 – 84 years</td>
<td>72 (38.7%)</td>
<td>23,234 (35.7%)</td>
</tr>
<tr>
<td>≥ 85 years</td>
<td>58 (31.2%)</td>
<td>10,733 (16.5%)</td>
</tr>
<tr>
<td>Male sex</td>
<td>50 (26.9%)</td>
<td>25,708 (39.5%)</td>
</tr>
<tr>
<td>Race/ethnicity</td>
<td></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>158 (84.9%)</td>
<td>53,578 (82.4%)</td>
</tr>
<tr>
<td>African American</td>
<td>15 (8.1%)</td>
<td>5,732 (8.8%)</td>
</tr>
<tr>
<td>Other</td>
<td>13 (7.0%)</td>
<td>5,714 (8.8%)</td>
</tr>
<tr>
<td>Region</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Northeast</td>
<td>30 (16.1%)</td>
<td>12,091 (18.6%)</td>
</tr>
<tr>
<td>Midwest</td>
<td>55 (29.6%)</td>
<td>14,436 (22.2%)</td>
</tr>
<tr>
<td>South</td>
<td>70 (37.6%)</td>
<td>26,759 (41.2%)</td>
</tr>
<tr>
<td>West</td>
<td>31 (16.7%)</td>
<td>11,738 (18.1%)</td>
</tr>
<tr>
<td>Calendar month of fall</td>
<td></td>
<td></td>
</tr>
<tr>
<td>January</td>
<td>15 (8.1%)</td>
<td>6,704 (10.3%)</td>
</tr>
<tr>
<td>February</td>
<td>17 (9.1%)</td>
<td>5,487 (8.4%)</td>
</tr>
<tr>
<td>March</td>
<td>13 (7.0%)</td>
<td>5,835 (9.0%)</td>
</tr>
<tr>
<td>April</td>
<td>12 (6.5%)</td>
<td>5,391 (8.3%)</td>
</tr>
<tr>
<td>May</td>
<td>9 (4.8%)</td>
<td>5,383 (8.3%)</td>
</tr>
<tr>
<td>June</td>
<td>13 (7.0%)</td>
<td>5,457 (8.4%)</td>
</tr>
<tr>
<td>July</td>
<td>20 (10.8%)</td>
<td>5,139 (7.9%)</td>
</tr>
<tr>
<td>August</td>
<td>22 (11.8%)</td>
<td>5,168 (7.9%)</td>
</tr>
<tr>
<td>September</td>
<td>11 (5.9%)</td>
<td>4,900 (7.5%)</td>
</tr>
<tr>
<td>October</td>
<td>24 (12.9%)</td>
<td>5,257 (8.1%)</td>
</tr>
<tr>
<td>November</td>
<td>17 (9.1%)</td>
<td>5,097 (7.8%)</td>
</tr>
<tr>
<td>December</td>
<td>13 (7.0%)</td>
<td>5,206 (8.0%)</td>
</tr>
<tr>
<td>History of Diabetes</td>
<td>34 (18.3%)</td>
<td>14,605 (22.5%)</td>
</tr>
<tr>
<td>History of CHD</td>
<td>47 (25.3%)</td>
<td>11,455 (17.6%)</td>
</tr>
<tr>
<td>History of heart failure</td>
<td>28 (15.1%)</td>
<td>4,579 (7.0%)</td>
</tr>
<tr>
<td>History of stroke</td>
<td>12 (6.5%)</td>
<td>1,813 (2.8%)</td>
</tr>
<tr>
<td>History of CKD</td>
<td>27 (14.5%)</td>
<td>7,945 (12.2%)</td>
</tr>
<tr>
<td>History of syncope</td>
<td>29 (15.6%)</td>
<td>5,145 (7.9%)</td>
</tr>
<tr>
<td>History of osteoporosis</td>
<td>66 (35.5%)</td>
<td>10,157 (15.6%)</td>
</tr>
<tr>
<td>History of depression</td>
<td>59 (31.7%)</td>
<td>8,332 (12.8%)</td>
</tr>
<tr>
<td>History of dementia</td>
<td>64 (34.4%)</td>
<td>8,587 (13.2%)</td>
</tr>
<tr>
<td>Number of medication classes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0-5</td>
<td>87 (46.8%)</td>
<td>36,716 (56.5%)</td>
</tr>
<tr>
<td>6-10</td>
<td>52 (28.0%)</td>
<td>17,791 (27.4%)</td>
</tr>
<tr>
<td>&gt;10</td>
<td>47 (25.3%)</td>
<td>10,517 (16.2%)</td>
</tr>
<tr>
<td>Charlson comorbidity index</td>
<td>104 (55.9%)</td>
<td>50,390 (77.5%)</td>
</tr>
<tr>
<td>----------------------------</td>
<td>-------------</td>
<td>----------------</td>
</tr>
<tr>
<td>≥ 4</td>
<td>36 (19.4%)</td>
<td>5,637 (8.7%)</td>
</tr>
<tr>
<td>Any hospitalization in the prior year</td>
<td>105 (56.5%)</td>
<td>19,482 (30.0%)</td>
</tr>
<tr>
<td>Skilled nursing facility stay in the prior year</td>
<td>54 (29.0%)</td>
<td>7,302 (11.2%)</td>
</tr>
</tbody>
</table>

Data are expressed as number (percentage).
Supplemental Table 2. Short-term odds ratios for a serious fall injury associated with initiation, adding a new drug class or antihypertensive medication titration using one* instead of six control periods

<table>
<thead>
<tr>
<th></th>
<th>Overall</th>
<th>Prior hypertension diagnosis</th>
<th>No recent hospitalization</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>OR (95% CI)</td>
<td>OR (95% CI)</td>
<td>OR (95% CI)</td>
</tr>
<tr>
<td>Initiation</td>
<td>1.39 (1.16, 1.68)</td>
<td>1.37 (1.08, 1.74)</td>
<td>1.32 (1.03, 1.68)</td>
</tr>
<tr>
<td>Addition of new class</td>
<td>1.12 (1.04, 1.21)</td>
<td>1.12 (1.03, 1.21)</td>
<td>1.16 (1.04, 1.29)</td>
</tr>
<tr>
<td>Titration</td>
<td>1.09 (1.04, 1.15)</td>
<td>1.08 (1.02, 1.14)</td>
<td>1.11 (1.03, 1.20)</td>
</tr>
</tbody>
</table>

Numbers in the table are odds ratio (95% confidence interval)
*60-74 days prior to the fall.
Supplemental Table 3. Number and percentage of Medicare beneficiaries initiating antihypertensive medication during the case period (0-14 days prior to fall) and control periods*

<table>
<thead>
<tr>
<th>Antihypertensive medication class</th>
<th>Overall Case (n=272)</th>
<th>Overall Control (n=1,201)</th>
<th>With hypertension diagnosis Case (n=159)</th>
<th>With hypertension diagnosis Control (n=701)</th>
<th>Without a recent hospitalization Case (n=146)</th>
<th>Without a recent hospitalization Control (n=635)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACE-inhibitors or angiotensin receptor blockers</td>
<td>84 (30.9%)</td>
<td>374 (31.1%)</td>
<td>55 (34.6%)</td>
<td>242 (34.5%)</td>
<td>51 (34.9%)</td>
<td>221 (34.8%)</td>
</tr>
<tr>
<td>Beta blockers</td>
<td>74 (27.2%)</td>
<td>351 (29.2%)</td>
<td>45 (28.3%)</td>
<td>217 (31.0%)</td>
<td>20 (13.7%)</td>
<td>151 (23.8%)</td>
</tr>
<tr>
<td>All diuretics</td>
<td>116 (42.6%)</td>
<td>474 (39.5%)</td>
<td>65 (40.9%)</td>
<td>250 (35.7%)</td>
<td>67 (45.9%)</td>
<td>245 (38.6%)</td>
</tr>
<tr>
<td>Thiazide-type</td>
<td>33 (12.1%)</td>
<td>165 (13.7%)</td>
<td>19 (11.9%)</td>
<td>92 (13.1%)</td>
<td>19 (13.0%)</td>
<td>107 (16.9%)</td>
</tr>
<tr>
<td>Loop</td>
<td>78 (28.7%)</td>
<td>276 (23.0%)</td>
<td>41 (25.8%)</td>
<td>144 (20.5%)</td>
<td>44 (30.1%)</td>
<td>111 (17.5%)</td>
</tr>
<tr>
<td>Potassium-sparing</td>
<td>Non-applicable</td>
<td>38 (3.2%)</td>
<td>Non-applicable</td>
<td>17 (2.4%)</td>
<td>Non-applicable</td>
<td>27 (4.3%)</td>
</tr>
<tr>
<td>Calcium channel blockers</td>
<td>40 (14.7%)</td>
<td>192 (16.0%)</td>
<td>29 (18.2%)</td>
<td>141 (20.1%)</td>
<td>14 (9.6%)</td>
<td>80 (12.6%)</td>
</tr>
<tr>
<td>Others*</td>
<td>21 (7.7%)</td>
<td>57 (4.7%)</td>
<td>13 (8.2%)</td>
<td>29 (4.1%)</td>
<td>12 (8.2%)</td>
<td>31 (4.9%)</td>
</tr>
<tr>
<td>Initiating &gt;1 antihypertensive class</td>
<td>55 (20.2%)</td>
<td>209 (17.4%)</td>
<td>41 (25.8%)</td>
<td>147 (21.0%)</td>
<td>19 (13.0%)</td>
<td>80 (12.6%)</td>
</tr>
</tbody>
</table>

Numbers and percentages in the column heading are those who initiated an antihypertensive medication during the case and control periods.
Non-applicable = cell sizes < 11 are suppressed as per Medicare data regulations.
This table includes all antihypertensive medications that are filled during the case and control periods.
*Six control periods: 30-44, 60-74, 90-104, 120-134, 150-164, and 180-194 days prior to the fall.
ACE = angiotensin-converting enzyme
Supplemental Table 4. Short-term odds ratios for a serious fall injury associated with initiation of antihypertensive medication by subgroup

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>N initiating in case period (N=272)</th>
<th>Odds ratio (95% CI)</th>
<th>p-value for homogeneity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age on fall date</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;75 years</td>
<td>84 (30.9%)</td>
<td>1.58 (1.25, 2.02)</td>
<td>0.233</td>
</tr>
<tr>
<td>75 – 84 years</td>
<td>94 (34.6%)</td>
<td>1.19 (0.96, 1.49)</td>
<td></td>
</tr>
<tr>
<td>≥ 85 years</td>
<td>94 (34.6%)</td>
<td>1.38 (1.10, 1.72)</td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>77 (28.3%)</td>
<td>1.40 (1.09, 1.79)</td>
<td>0.803</td>
</tr>
<tr>
<td>Female</td>
<td>195 (71.7%)</td>
<td>1.34 (1.15, 1.57)</td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>244 (89.7%)</td>
<td>1.37 (1.19, 1.57)</td>
<td>0.799</td>
</tr>
<tr>
<td>Non-white</td>
<td>28 (10.3%)</td>
<td>1.24 (0.67, 2.31)</td>
<td></td>
</tr>
<tr>
<td>Region</td>
<td></td>
<td></td>
<td>0.557</td>
</tr>
<tr>
<td>Northeast</td>
<td>47 (17.3%)</td>
<td>1.35 (0.98, 1.85)</td>
<td></td>
</tr>
<tr>
<td>Midwest</td>
<td>69 (25.4%)</td>
<td>1.42 (1.09, 1.84)</td>
<td></td>
</tr>
<tr>
<td>South</td>
<td>110 (40.4%)</td>
<td>1.46 (1.18, 1.79)</td>
<td></td>
</tr>
<tr>
<td>West</td>
<td>46 (16.9%)</td>
<td>1.12 (0.82, 1.53)</td>
<td></td>
</tr>
<tr>
<td>Calendar month of fall</td>
<td></td>
<td></td>
<td>0.591</td>
</tr>
<tr>
<td>January</td>
<td>22 (8.1%)</td>
<td>1.28 (0.81, 2.03)</td>
<td></td>
</tr>
<tr>
<td>February</td>
<td>23 (8.5%)</td>
<td>2.19 (1.36, 3.53)</td>
<td></td>
</tr>
<tr>
<td>March</td>
<td>15 (5.5%)</td>
<td>0.97 (0.56, 1.67)</td>
<td></td>
</tr>
<tr>
<td>April</td>
<td>24 (8.8%)</td>
<td>1.52 (0.97, 2.37)</td>
<td></td>
</tr>
<tr>
<td>May</td>
<td>19 (7.0%)</td>
<td>1.27 (0.77, 2.08)</td>
<td></td>
</tr>
<tr>
<td>June</td>
<td>21 (7.7%)</td>
<td>1.30 (0.81, 2.08)</td>
<td></td>
</tr>
<tr>
<td>July</td>
<td>27 (8.5%)</td>
<td>1.62 (1.06, 2.48)</td>
<td></td>
</tr>
<tr>
<td>August</td>
<td>21 (7.7%)</td>
<td>1.08 (0.68, 1.71)</td>
<td></td>
</tr>
<tr>
<td>September</td>
<td>23 (8.5%)</td>
<td>1.24 (0.79, 1.95)</td>
<td></td>
</tr>
<tr>
<td>October</td>
<td>23 (8.5%)</td>
<td>1.09 (0.70, 1.69)</td>
<td></td>
</tr>
<tr>
<td>November</td>
<td>24 (8.8%)</td>
<td>1.53 (0.98, 2.40)</td>
<td></td>
</tr>
<tr>
<td>December</td>
<td>30 (11.0%)</td>
<td>1.62 (1.08, 2.43)</td>
<td></td>
</tr>
<tr>
<td>No Diabetes</td>
<td>218 (80.1%)</td>
<td>1.34 (1.16, 1.55)</td>
<td>0.671</td>
</tr>
<tr>
<td>Diabetes</td>
<td>54 (19.9%)</td>
<td>1.44 (1.07, 1.94)</td>
<td></td>
</tr>
<tr>
<td>No CHD</td>
<td>206 (75.7%)</td>
<td>1.35 (1.16, 1.57)</td>
<td>0.898</td>
</tr>
<tr>
<td>CHD</td>
<td>66 (24.3%)</td>
<td>1.38 (1.06, 1.80)</td>
<td></td>
</tr>
<tr>
<td>No heart failure</td>
<td>236 (86.8%)</td>
<td>1.39 (1.21, 1.60)</td>
<td>0.421</td>
</tr>
<tr>
<td>Heart failure</td>
<td>36 (13.2%)</td>
<td>1.19 (0.83, 1.70)</td>
<td></td>
</tr>
<tr>
<td>No stroke</td>
<td>260 (95.6%)</td>
<td>1.37 (1.20, 1.57)</td>
<td>0.472</td>
</tr>
<tr>
<td>Stroke</td>
<td>12 (4.4%)</td>
<td>1.09 (0.59, 2.02)</td>
<td></td>
</tr>
<tr>
<td>No CKD</td>
<td>225 (82.7%)</td>
<td>1.37 (1.19, 1.59)</td>
<td>0.712</td>
</tr>
<tr>
<td>CKD</td>
<td>47 (17.3%)</td>
<td>1.29 (0.94, 1.76)</td>
<td></td>
</tr>
<tr>
<td>No syncope</td>
<td>239 (87.4%)</td>
<td>1.39 (1.21, 1.60)</td>
<td>0.402</td>
</tr>
<tr>
<td>Syncope</td>
<td>33 (12.1%)</td>
<td>1.17 (0.81, 1.70)</td>
<td></td>
</tr>
<tr>
<td>No osteoporosis</td>
<td>211 (77.6%)</td>
<td>1.39 (1.20, 1.62)</td>
<td>0.529</td>
</tr>
<tr>
<td>Osteoporosis</td>
<td>61 (22.4%)</td>
<td>1.26 (0.95, 1.66)</td>
<td></td>
</tr>
<tr>
<td>No depression</td>
<td>202 (74.3%)</td>
<td>1.35 (1.16, 1.57)</td>
<td>0.885</td>
</tr>
<tr>
<td>Depression</td>
<td>70 (25.7%)</td>
<td>1.38 (1.07, 1.79)</td>
<td></td>
</tr>
<tr>
<td>Category</td>
<td>Count (%)</td>
<td>Hazard Ratio (95% CI)</td>
<td>p-value</td>
</tr>
<tr>
<td>--------------------------------</td>
<td>-----------</td>
<td>-----------------------</td>
<td>---------</td>
</tr>
<tr>
<td>No dementia</td>
<td>204 (75.0%)</td>
<td>1.42 (1.22, 1.65)</td>
<td>0.308</td>
</tr>
<tr>
<td>dementia</td>
<td>68 (25.0%)</td>
<td>1.21 (0.93, 1.57)</td>
<td></td>
</tr>
<tr>
<td>Number of medication classes</td>
<td></td>
<td></td>
<td>0.173</td>
</tr>
<tr>
<td>0–5 classes</td>
<td>75 (27.6%)</td>
<td>1.69 (1.30, 2.18)</td>
<td></td>
</tr>
<tr>
<td>6 – 10 classes</td>
<td>90 (33.1%)</td>
<td>1.24 (0.99, 1.55)</td>
<td></td>
</tr>
<tr>
<td>&gt;10 classes</td>
<td>107 (39.3%)</td>
<td>1.29 (1.05, 1.59)</td>
<td></td>
</tr>
<tr>
<td>Charlson comorbidity index</td>
<td></td>
<td></td>
<td>0.659</td>
</tr>
<tr>
<td>0</td>
<td>167 (61.4%)</td>
<td>1.34 (1.14, 1.59)</td>
<td></td>
</tr>
<tr>
<td>1-3</td>
<td>61 (22.4%)</td>
<td>1.51 (1.14, 1.99)</td>
<td></td>
</tr>
<tr>
<td>≥ 4</td>
<td>44 (16.2%)</td>
<td>1.24 (0.90, 1.71)</td>
<td></td>
</tr>
<tr>
<td>No hospitalization in the prior year</td>
<td>146 (53.7%)</td>
<td>1.38 (1.15, 1.65)</td>
<td>0.810</td>
</tr>
<tr>
<td>Hospitalization in the prior year</td>
<td>126 (46.3%)</td>
<td>1.34 (1.10, 1.62)</td>
<td></td>
</tr>
<tr>
<td>No skills nursing facility in the prior year</td>
<td>218 (80.1%)</td>
<td>1.34 (1.16, 1.55)</td>
<td>0.671</td>
</tr>
<tr>
<td>Skills nursing facility in the prior year</td>
<td>54 (19.9%)</td>
<td>1.44 (1.07, 1.94)</td>
<td></td>
</tr>
</tbody>
</table>

This analysis used six control periods: 30-44, 60-74, 90-104, 120-134, 150-164, and 180-194 days prior to the fall.

CHD = coronary heart disease, CKD = chronic kidney disease
### Supplemental Table 5. Short-term odds ratios for a serious fall injury associated with addition of new class by subgroup

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>N adding new class in case period (N=1,508)</th>
<th>Odds ratio (95% CI)</th>
<th>p-value for homogeneity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age on fall date</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;75 years</td>
<td>370 (24.5%)</td>
<td>1.15 (1.02, 1.28)</td>
<td>0.076</td>
</tr>
<tr>
<td>85 – 84 years</td>
<td>591 (39.2%)</td>
<td>1.09 (1.00, 1.19)</td>
<td></td>
</tr>
<tr>
<td>≥ 85 years</td>
<td>547 (36.3%)</td>
<td>1.26 (1.15, 1.39)</td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>1,145 (75.9%)</td>
<td>1.17 (1.04, 1.31)</td>
<td>0.931</td>
</tr>
<tr>
<td>Female</td>
<td>363 (24.1%)</td>
<td>1.16 (1.09, 1.24)</td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>1,314 (87.1%)</td>
<td>1.16 (1.10, 1.23)</td>
<td>0.917</td>
</tr>
<tr>
<td>Non-white</td>
<td>194 (22.9%)</td>
<td>1.14 (0.90, 1.43)</td>
<td></td>
</tr>
<tr>
<td>Region</td>
<td></td>
<td></td>
<td>0.765</td>
</tr>
<tr>
<td>Northeast</td>
<td>259 (17.2%)</td>
<td>1.10 (0.97, 1.26)</td>
<td></td>
</tr>
<tr>
<td>Midwest</td>
<td>368 (24.4%)</td>
<td>1.17 (1.05, 1.31)</td>
<td></td>
</tr>
<tr>
<td>South</td>
<td>629 (41.7%)</td>
<td>1.19 (1.09, 1.30)</td>
<td></td>
</tr>
<tr>
<td>West</td>
<td>252 (16.7%)</td>
<td>1.13 (0.98, 1.29)</td>
<td></td>
</tr>
<tr>
<td>Calendar month of fall</td>
<td></td>
<td></td>
<td>0.238</td>
</tr>
<tr>
<td>January</td>
<td>121 (8.0%)</td>
<td>1.20 (0.99, 1.47)</td>
<td></td>
</tr>
<tr>
<td>February</td>
<td>110 (7.3%)</td>
<td>1.27 (1.03, 1.57)</td>
<td></td>
</tr>
<tr>
<td>March</td>
<td>110 (7.3%)</td>
<td>1.14 (0.93, 1.40)</td>
<td></td>
</tr>
<tr>
<td>April</td>
<td>122 (8.1%)</td>
<td>1.26 (1.03, 1.54)</td>
<td></td>
</tr>
<tr>
<td>May</td>
<td>126 (8.4%)</td>
<td>1.31 (1.08, 1.59)</td>
<td></td>
</tr>
<tr>
<td>June</td>
<td>128 (8.5%)</td>
<td>1.25 (1.03, 1.52)</td>
<td></td>
</tr>
<tr>
<td>July</td>
<td>138 (9.2%)</td>
<td>1.21 (1.00, 1.45)</td>
<td></td>
</tr>
<tr>
<td>August</td>
<td>108 (7.2%)</td>
<td>0.86 (0.70, 1.05)</td>
<td></td>
</tr>
<tr>
<td>September</td>
<td>132 (8.8%)</td>
<td>1.15 (0.95, 1.39)</td>
<td></td>
</tr>
<tr>
<td>October</td>
<td>130 (8.6%)</td>
<td>1.06 (0.88, 1.29)</td>
<td></td>
</tr>
<tr>
<td>November</td>
<td>132 (8.8%)</td>
<td>1.16 (0.96, 1.40)</td>
<td></td>
</tr>
<tr>
<td>December</td>
<td>151 (10.0%)</td>
<td>1.17 (0.98, 1.40)</td>
<td></td>
</tr>
<tr>
<td>No Diabetes</td>
<td>1,042 (69.1%)</td>
<td>1.21 (1.13, 1.30)</td>
<td>0.032</td>
</tr>
<tr>
<td>Diabetes</td>
<td>466 (30.9%)</td>
<td>1.06 (0.96, 1.17)</td>
<td></td>
</tr>
<tr>
<td>No CHD</td>
<td>959 (63.6%)</td>
<td>1.20 (1.12, 1.29)</td>
<td>0.120</td>
</tr>
<tr>
<td>CHD</td>
<td>549 (36.4%)</td>
<td>1.10 (1.00, 1.20)</td>
<td></td>
</tr>
<tr>
<td>No heart failure</td>
<td>1,104 (73.2%)</td>
<td>1.23 (1.16, 1.32)</td>
<td>0.001</td>
</tr>
<tr>
<td>Heart failure</td>
<td>404 (26.8%)</td>
<td>1.00 (0.90, 1.11)</td>
<td></td>
</tr>
<tr>
<td>No stroke</td>
<td>1,433 (95.0%)</td>
<td>1.17 (1.11, 1.24)</td>
<td>0.172</td>
</tr>
<tr>
<td>Stroke</td>
<td>75 (5.0%)</td>
<td>0.98 (0.77, 1.26)</td>
<td></td>
</tr>
<tr>
<td>No CKD</td>
<td>1,040 (69.0%)</td>
<td>1.20 (1.12, 1.29)</td>
<td>0.077</td>
</tr>
<tr>
<td>CKD</td>
<td>468 (31.0%)</td>
<td>1.08 (0.98, 1.19)</td>
<td></td>
</tr>
<tr>
<td>No syncope</td>
<td>1,267 (84.0%)</td>
<td>1.17 (1.10, 1.24)</td>
<td>0.775</td>
</tr>
<tr>
<td>Syncope</td>
<td>241 (16.0%)</td>
<td>1.14 (0.99, 1.31)</td>
<td></td>
</tr>
<tr>
<td>No osteoporosis</td>
<td>1,160 (77.0%)</td>
<td>1.15 (1.07, 1.22)</td>
<td>0.361</td>
</tr>
<tr>
<td>Osteoporosis</td>
<td>348 (23.1%)</td>
<td>1.22 (1.08, 1.37)</td>
<td></td>
</tr>
<tr>
<td>No depression</td>
<td>1,129 (74.9%)</td>
<td>1.18 (1.11, 1.26)</td>
<td>0.366</td>
</tr>
<tr>
<td>Depression</td>
<td>379 (25.1%)</td>
<td>1.11 (0.99, 1.24)</td>
<td></td>
</tr>
<tr>
<td>Category</td>
<td>Count (Percentage)</td>
<td>Odds Ratio (95% CI)</td>
<td>P-value</td>
</tr>
<tr>
<td>-----------------------------------------</td>
<td>--------------------</td>
<td>---------------------</td>
<td>---------</td>
</tr>
<tr>
<td>No dementia</td>
<td>1,156 (76.7%)</td>
<td>1.14 (1.07, 1.22)</td>
<td>0.257</td>
</tr>
<tr>
<td>Dementia</td>
<td>352 (23.3%)</td>
<td>1.23 (1.10, 1.38)</td>
<td></td>
</tr>
<tr>
<td>Number of medication classes</td>
<td></td>
<td></td>
<td>0.002</td>
</tr>
<tr>
<td>0–5</td>
<td>138 (9.2%)</td>
<td>1.60 (1.32, 1.93)</td>
<td></td>
</tr>
<tr>
<td>6–10</td>
<td>372 (24.7%)</td>
<td>1.20 (1.07, 1.34)</td>
<td></td>
</tr>
<tr>
<td>&gt;10</td>
<td>998 (66.2%)</td>
<td>1.11 (1.03, 1.18)</td>
<td></td>
</tr>
<tr>
<td>Charlson comorbidity index</td>
<td></td>
<td></td>
<td>0.321</td>
</tr>
<tr>
<td>0</td>
<td>805 (53.4%)</td>
<td>1.21 (1.12, 1.30)</td>
<td></td>
</tr>
<tr>
<td>1–3</td>
<td>308 (20.4%)</td>
<td>1.13 (1.00, 1.28)</td>
<td></td>
</tr>
<tr>
<td>≥4</td>
<td>395 (26.2%)</td>
<td>1.10 (0.98, 1.22)</td>
<td></td>
</tr>
<tr>
<td>No hospitalization in the prior year</td>
<td></td>
<td></td>
<td>0.313</td>
</tr>
<tr>
<td>Hospitalization in the prior year</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No skills nursing facility in the prior year</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Skills nursing facility in the prior year</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

This analysis used six control periods: 30-44, 60-74, 90-104, 120-134, 150-164, and 180-194 days prior to the fall.

CHD = coronary heart disease, CKD = chronic kidney disease
Supplemental Table 6. Short-term odds ratios for a serious fall injury associated with titration of antihypertensive medication by subgroup

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>N titration in case period (N=3,113)</th>
<th>Odds ratio (95% CI)</th>
<th>p-value for homogeneity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age on fall date</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;75 years</td>
<td>683 (21.9%)</td>
<td>1.05 (0.96, 1.14)</td>
<td>0.024</td>
</tr>
<tr>
<td>85 – 84 years</td>
<td>1,219 (39.2%)</td>
<td>1.11 (1.04, 1.18)</td>
<td></td>
</tr>
<tr>
<td>≥ 85 years</td>
<td>1,211 (38.9%)</td>
<td>1.21 (1.13, 1.29)</td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>734 (23.6%)</td>
<td>1.16 (1.07, 1.26)</td>
<td>0.462</td>
</tr>
<tr>
<td>Female</td>
<td>2,379 (76.4%)</td>
<td>1.12 (1.07, 1.17)</td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>2,737 (87.9%)</td>
<td>1.14 (1.09, 1.19)</td>
<td>0.319</td>
</tr>
<tr>
<td>Non-white</td>
<td>376 (12.1%)</td>
<td>1.09 (0.92, 1.29)</td>
<td></td>
</tr>
<tr>
<td>Region</td>
<td></td>
<td></td>
<td>0.108</td>
</tr>
<tr>
<td>Northeast</td>
<td>558 (17.9%)</td>
<td>1.06 (0.96, 1.16)</td>
<td></td>
</tr>
<tr>
<td>Midwest</td>
<td>843 (27.1%)</td>
<td>1.22 (1.12, 1.31)</td>
<td></td>
</tr>
<tr>
<td>South</td>
<td>1,232 (39.6%)</td>
<td>1.13 (1.06, 1.20)</td>
<td></td>
</tr>
<tr>
<td>West</td>
<td>480 (15.4%)</td>
<td>1.08 (0.97, 1.19)</td>
<td></td>
</tr>
<tr>
<td>Calendar month of fall</td>
<td></td>
<td></td>
<td>0.436</td>
</tr>
<tr>
<td>January</td>
<td>243 (7.8%)</td>
<td>1.10 (0.95, 1.27)</td>
<td></td>
</tr>
<tr>
<td>February</td>
<td>248 (8.0%)</td>
<td>1.30 (1.13, 1.50)</td>
<td></td>
</tr>
<tr>
<td>March</td>
<td>219 (7.0%)</td>
<td>1.04 (0.90, 1.21)</td>
<td></td>
</tr>
<tr>
<td>April</td>
<td>240 (7.7%)</td>
<td>1.16 (1.01, 1.34)</td>
<td></td>
</tr>
<tr>
<td>May</td>
<td>237 (7.6%)</td>
<td>1.14 (0.99, 1.32)</td>
<td></td>
</tr>
<tr>
<td>June</td>
<td>258 (8.3%)</td>
<td>1.23 (1.07, 1.42)</td>
<td></td>
</tr>
<tr>
<td>July</td>
<td>280 (9.0%)</td>
<td>1.19 (1.04, 1.36)</td>
<td></td>
</tr>
<tr>
<td>August</td>
<td>275 (8.8%)</td>
<td>1.04 (0.91, 1.19)</td>
<td></td>
</tr>
<tr>
<td>September</td>
<td>281 (9.0%)</td>
<td>1.19 (1.04, 1.36)</td>
<td></td>
</tr>
<tr>
<td>October</td>
<td>278 (8.9%)</td>
<td>1.05 (0.92, 1.20)</td>
<td></td>
</tr>
<tr>
<td>November</td>
<td>251 (8.1%)</td>
<td>1.05 (0.91, 1.21)</td>
<td></td>
</tr>
<tr>
<td>December</td>
<td>303 (9.7%)</td>
<td>1.11 (0.98, 1.26)</td>
<td></td>
</tr>
<tr>
<td>No Diabetes</td>
<td>2,035 (65.4%)</td>
<td>1.15 (1.09, 1.21)</td>
<td>0.263</td>
</tr>
<tr>
<td>Diabetes</td>
<td>1,078 (34.6%)</td>
<td>1.09 (1.02, 1.17)</td>
<td></td>
</tr>
<tr>
<td>No CHD</td>
<td>1,884 (60.5%)</td>
<td>1.15 (1.10, 1.22)</td>
<td>0.169</td>
</tr>
<tr>
<td>CHD</td>
<td>1,229 (39.5%)</td>
<td>1.09 (1.02, 1.16)</td>
<td></td>
</tr>
<tr>
<td>No heart failure</td>
<td>2,125 (68.3%)</td>
<td>1.17 (1.11, 1.23)</td>
<td>0.011</td>
</tr>
<tr>
<td>Heart failure</td>
<td>988 (31.7%)</td>
<td>1.05 (0.97, 1.12)</td>
<td></td>
</tr>
<tr>
<td>No stroke</td>
<td>2,962 (95.1%)</td>
<td>1.14 (1.09, 1.18)</td>
<td>0.155</td>
</tr>
<tr>
<td>Stroke</td>
<td>151 (4.9%)</td>
<td>0.99 (0.83, 1.19)</td>
<td></td>
</tr>
<tr>
<td>No CKD</td>
<td>2,074 (66.6%)</td>
<td>1.16 (1.11, 1.22)</td>
<td>0.047</td>
</tr>
<tr>
<td>CKD</td>
<td>1,039 (33.4%)</td>
<td>1.07 (0.99, 1.14)</td>
<td></td>
</tr>
<tr>
<td>No syncope</td>
<td>2,645 (85.0%)</td>
<td>1.14 (1.09, 1.19)</td>
<td>0.225</td>
</tr>
<tr>
<td>Syncope</td>
<td>468 (15.0%)</td>
<td>1.06 (0.96, 1.18)</td>
<td></td>
</tr>
<tr>
<td>No osteoporosis</td>
<td>2,393 (76.9%)</td>
<td>1.11 (1.06, 1.16)</td>
<td>0.183</td>
</tr>
<tr>
<td>Osteoporosis</td>
<td>720 (23.1%)</td>
<td>1.19 (1.09, 1.29)</td>
<td></td>
</tr>
<tr>
<td>No depression</td>
<td>2,351 (75.5%)</td>
<td>1.15 (1.10, 1.21)</td>
<td>0.107</td>
</tr>
<tr>
<td>Depression</td>
<td>762 (24.5%)</td>
<td>1.07 (0.98, 1.16)</td>
<td></td>
</tr>
<tr>
<td>Category</td>
<td>Count</td>
<td>Rate</td>
<td>95% CI</td>
</tr>
<tr>
<td>----------------------------------------------</td>
<td>--------</td>
<td>----------</td>
<td>-----------</td>
</tr>
<tr>
<td>No dementia</td>
<td>2,366</td>
<td>1.11</td>
<td>(1.06, 1.16)</td>
</tr>
<tr>
<td>dementia</td>
<td>747</td>
<td>1.19</td>
<td>(1.09, 1.29)</td>
</tr>
<tr>
<td>Number of medication classes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0–5</td>
<td>204</td>
<td>1.31</td>
<td>(1.13, 1.53)</td>
</tr>
<tr>
<td>6 – 10</td>
<td>698</td>
<td>1.14</td>
<td>(1.05, 1.24)</td>
</tr>
<tr>
<td>&gt;10</td>
<td>2,211</td>
<td>1.11</td>
<td>(1.06, 1.16)</td>
</tr>
<tr>
<td>Charlson comorbidity index</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>1,657</td>
<td>1.15</td>
<td>(1.09, 1.21)</td>
</tr>
<tr>
<td>1–3</td>
<td>587</td>
<td>1.11</td>
<td>(1.01, 1.22)</td>
</tr>
<tr>
<td>≥ 4</td>
<td>869</td>
<td>1.11</td>
<td>(1.03, 1.20)</td>
</tr>
<tr>
<td>No hospitalization in the prior year</td>
<td>1,432</td>
<td>1.13</td>
<td>(1.07, 1.20)</td>
</tr>
<tr>
<td>Hospitalization in the prior year</td>
<td>1,681</td>
<td>1.13</td>
<td>(1.07, 1.19)</td>
</tr>
<tr>
<td>No skills nursing facility in the prior year</td>
<td>2,427</td>
<td>1.12</td>
<td>(1.07, 1.17)</td>
</tr>
<tr>
<td>Skills nursing facility in the prior year</td>
<td>686</td>
<td>1.15</td>
<td>(1.06, 1.25)</td>
</tr>
</tbody>
</table>

This analysis used six control periods: 30-44, 60-74, 90-104, 120-134, 150-164, and 180-194 days prior to the fall.

CHD = coronary heart disease, CKD = chronic kidney disease
Supplemental Table 7. Short-term odds ratios for a serious fall injury associated with initiation of antihypertensive medication by class and number of antihypertensive medication

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>N in case period (N=272)</th>
<th>Odds ratio (95% CI)</th>
<th>p-value for homogeneity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antihypertensive medication class</td>
<td></td>
<td></td>
<td>0.816</td>
</tr>
<tr>
<td>ACE-inhibitors or angiotensin receptor blockers</td>
<td>84 (30.9%)</td>
<td>1.35 (1.06, 1.71)</td>
<td></td>
</tr>
<tr>
<td>Beta blockers</td>
<td>74 (27.2%)</td>
<td>1.26 (0.98, 1.63)</td>
<td></td>
</tr>
<tr>
<td>Calcium channel blockers</td>
<td>40 (14.7%)</td>
<td>1.25 (0.89, 1.76)</td>
<td></td>
</tr>
<tr>
<td>Any diuretic</td>
<td>116 (42.7%)</td>
<td>1.47 (1.20, 1.80)</td>
<td></td>
</tr>
<tr>
<td>Type of diuretic</td>
<td></td>
<td></td>
<td>0.334</td>
</tr>
<tr>
<td>Thiazide diuretic</td>
<td>33 (12.1%)</td>
<td>1.20 (0.83, 1.74)</td>
<td></td>
</tr>
<tr>
<td>Loop diuretic</td>
<td>78 (28.7%)</td>
<td>1.70 (1.32, 2.18)</td>
<td></td>
</tr>
<tr>
<td>Potassium sparing diuretic</td>
<td>8 (2.9%)</td>
<td>1.26 (0.59, 2.71)</td>
<td></td>
</tr>
<tr>
<td>Number of classes</td>
<td></td>
<td></td>
<td>0.280</td>
</tr>
<tr>
<td>One class</td>
<td>217 (79.8%)</td>
<td>1.31 (1.13, 1.52)</td>
<td></td>
</tr>
<tr>
<td>2 or more classes</td>
<td>55 (20.2%)</td>
<td>1.58 (1.17, 2.13)</td>
<td></td>
</tr>
</tbody>
</table>

This analysis used six control periods: 30-44, 60-74, 90-104, 120-134, 150-164, and 180-194 days prior to the fall.

ACE = angiotensin-converting enzyme
Supplemental Table 8. Short-term odds ratios for a serious fall injury associated with addition of new class of antihypertensive medication by class and number of antihypertensive medication

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>N in case period (N=1,508)</th>
<th>Odds ratio (95% CI)</th>
<th>p-value for homogeneity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antihypertensive medication class</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ACE-inhibitors or angiotensin receptor blockers</td>
<td>379 (25.1%)</td>
<td>1.17 (1.05, 1.31)</td>
<td>0.994</td>
</tr>
<tr>
<td>Beta blockers</td>
<td>273 (18.1%)</td>
<td>1.16 (1.02, 1.32)</td>
<td></td>
</tr>
<tr>
<td>Calcium channel blockers</td>
<td>241 (16.0%)</td>
<td>1.16 (1.01, 1.33)</td>
<td></td>
</tr>
<tr>
<td>Any diuretic</td>
<td>593 (39.3%)</td>
<td>1.16 (1.06, 1.27)</td>
<td></td>
</tr>
<tr>
<td>Type of diuretic</td>
<td></td>
<td></td>
<td>0.086</td>
</tr>
<tr>
<td>Thiazide diuretic</td>
<td>195 (12.9%)</td>
<td>1.11 (0.95, 1.29)</td>
<td></td>
</tr>
<tr>
<td>Loop diuretic</td>
<td>375 (24.9%)</td>
<td>1.22 (1.09, 1.37)</td>
<td></td>
</tr>
<tr>
<td>Potassium sparing diuretic</td>
<td>27 (1.8%)</td>
<td>0.80 (0.53, 1.19)</td>
<td></td>
</tr>
<tr>
<td>Number of classes</td>
<td></td>
<td></td>
<td>0.089</td>
</tr>
<tr>
<td>One class</td>
<td>1327 (88.0%)</td>
<td>1.14 (1.08, 1.21)</td>
<td></td>
</tr>
<tr>
<td>2 or more classes</td>
<td>181 (12.0%)</td>
<td>1.32 (1.13, 1.55)</td>
<td></td>
</tr>
</tbody>
</table>

This analysis used six control periods: 30-44, 60-74, 90-104, 120-134, 150-164, and 180-194 days prior to the fall.

ACE = angiotensin-converting enzyme
Supplemental Table 9. Short-term and long-term odds ratios for a serious fall injury associated with initiation, addition of new class, and titration of antihypertensive medication using one control period

<table>
<thead>
<tr>
<th>Case period</th>
<th>Overall</th>
<th>Prior hypertension diagnosis</th>
<th>No recent hospitalization</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Initiation</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0-14 days*</td>
<td>1.39 (1.16, 1.68)</td>
<td>1.37 (1.08, 1.74)</td>
<td>1.32 (1.03, 1.68)</td>
</tr>
<tr>
<td>30-44 days†</td>
<td>1.00 (0.82, 1.22)</td>
<td>1.15 (0.89, 1.47)</td>
<td>0.98 (0.74, 1.29)</td>
</tr>
<tr>
<td>60-74 days‡</td>
<td>1.01 (0.82, 1.23)</td>
<td>1.03 (0.79, 1.33)</td>
<td>1.04 (0.80, 1.35)</td>
</tr>
<tr>
<td>90-104 days§</td>
<td>1.01 (0.83, 1.23)</td>
<td>1.01 (0.78, 1.31)</td>
<td>0.98 (0.75, 1.29)</td>
</tr>
<tr>
<td><strong>Addition of new class</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0-14 days*</td>
<td>1.12 (1.04, 1.21)</td>
<td>1.12 (1.03, 1.21)</td>
<td>1.16 (1.04, 1.29)</td>
</tr>
<tr>
<td>30-44 days†</td>
<td>1.06 (0.98, 1.14)</td>
<td>1.05 (0.97, 1.14)</td>
<td>1.02 (0.91, 1.14)</td>
</tr>
<tr>
<td>60-74 days‡</td>
<td>1.03 (0.95, 1.11)</td>
<td>1.02 (0.94, 1.11)</td>
<td>0.97 (0.87, 1.09)</td>
</tr>
<tr>
<td>90-104 days§</td>
<td>1.04 (0.96, 1.13)</td>
<td>1.04 (0.96, 1.14)</td>
<td>1.06 (0.94, 1.20)</td>
</tr>
<tr>
<td><strong>Titration</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0-14 days*</td>
<td>1.09 (1.04, 1.15)</td>
<td>1.08 (1.02, 1.14)</td>
<td>1.11 (1.03, 1.20)</td>
</tr>
<tr>
<td>30-44 days†</td>
<td>1.02 (0.97, 1.08)</td>
<td>1.03 (0.98, 1.10)</td>
<td>1.00 (0.92, 1.08)</td>
</tr>
<tr>
<td>60-74 days‡</td>
<td>1.03 (0.97, 1.09)</td>
<td>1.03 (0.97, 1.09)</td>
<td>0.97 (0.89, 1.05)</td>
</tr>
<tr>
<td>90-104 days§</td>
<td>1.07 (1.01, 1.13)</td>
<td>1.07 (1.01, 1.14)</td>
<td>1.05 (0.97, 1.14)</td>
</tr>
</tbody>
</table>

Numbers in table are odds ratio (95% confidence interval)

Control periods:
*60-74 days prior to the fall.
†90-104 days prior to the fall.
‡120-134 days prior to the fall.
§150-164 days prior to the fall.
Supplemental Figure 1. Flow diagram for the analysis of Medicare beneficiaries in the retrospective cohort study.

Filled antihypertensive medication between January 1, 2007 and December 31, 2011 (N=1,525,899)

In 5% random sample of Medicare beneficiaries; alive and have 365 continuous days of Medicare Part A, B, D but not C coverage; and no claims for antihypertensive medication during the 365 look back period (N=173,709)

With hypertension, defined by one or more outpatient physician evaluation and management claims with International Classification of Diseases, 9th Revision (ICD-9) diagnoses of 401.x (malignant, benign or unspecified essential hypertension) during the 365 days prior to each beneficiary’s first antihypertensive medication fill (N=86,450)

Age ≥ 65 years old and < 110 years old at the start of the look back period* and with continuous residence in the US during the look back period (N=65,210)

*The start of the look back period is the 365 days prior to the first antihypertensive medication fill.
Supplemental Figure 2. Flow diagram for the analysis of Medicare beneficiaries in the case-crossover study

Had a serious fall injury between July 1, 2007 and December 31, 2012 (N=312,542 with a serious fall injury)

In national 5% random sample of Medicare beneficiaries; and have 560 continuous days of Medicare Part A, B, and D but not C coverage prior to date of the first serious fall injury (N=114,112 with a serious fall injury)

Alive with age ≥ 65 years old and < 110 years old at the beginning of the look back period; and with continuous residence in the US during the look back period (N=90,127)